Bristol Myers Squibb (NYSE: BMY) reported third-quarter 2025 revenue of $12.2 billion, up 3% year-on-year, with non-GAAP earnings per share of $1.63. Growth was driven by the company’s newer products, ...

Danish pharma major Novo Nordisk today confirmed that it submitted an unsolicited proposal to acquire Metsera, aiming to ...

Swiss drug developer Oculis Holding today announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary ...

Swiss generics and biosimilars drugmaker Sandoz today presented its net-sales performance for the nine months and third ...

Austrian biotech VALANX Biotech has appointed Klaus Orlinger as chief scientific officer, reinforcing its leadership as the ...

South Korea-based Samsung Life Science Fund, created jointly between Samsung Biologics, Samsung Bioepis, and Samsung C&T , ...